Additionally, a Phase II clinical trial (NCT03484923) evaluating the efficacy of Ieramlimab combined with Spartalizumab in patients with PD-1 inhibitor-resistant melanoma indicated promising antitumor effects against LAG3-positive metastatic melanoma (61). This evidence concerns the gene PDCD1 and metastatic melanoma.